secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGM Biosciences, Inc. (—)
CIK:        0001496323
Form:       8-K
Filed at:   2024-10-03T23:59:59+00:00
Accession:  0001193125-24-232252
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IGM Biosciences pivots to autoimmunity, ends aplitabart work, names new CEO Mary Beth Harler
--------------------------------------------------------------------------------

- Strategic pivot to focus exclusively on T cell engagers for autoimmune diseases; aplitabart and other oncology programs minimized.
- Mary Beth Harler, M.D. appointed CEO and director effective Sept 30, 2024; Fred Schwarzer resigns as CEO and director.
- Bruce Keyt, Ph.D. steps down as CSO; Chris Takimoto, M.D., Ph.D. resigns as CMO effective Oct 1, 2024.
- Cash runway extended into 2027; reduction in force expected; activities substantially complete by Q1 2025.
- Imvotamab (CD20xCD3) ongoing in RA, SLE, myositis; IGM-2644 (CD38xCD3) expected to enter clinic for gMG by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1496323/000119312524232252/0001193125-24-232252-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1496323/000119312524232252/d860501d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-232252

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer